已收盤 02-06 16:00:00 美东时间
+1.760
+3.82%
今日重点评级关注:韦德布什:维持Replimune Group"跑赢大市"评级,目标价从18美元升至19美元;巴克莱:维持CytomX Therapeutics"超配"评级,目标价从8美元升至10美元
02-05 11:28
Benchmark analyst Ben Klieve maintains TAT Technologies (NASDAQ:TATT) with a Buy and raises the price target from $53 to $58.
02-04 22:29
今日重点评级关注:Ascendiant Capital:维持Maison Solutions"买入"评级,目标价从4.25美元升至4.5美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从39美元升至50美元
2025-12-31 10:25
Lake Street analyst Jaeson Schmidt assumes TAT Technologies (NASDAQ:TATT) with a Buy rating and raises Price Target to $53.
2025-12-31 01:12
今日重点评级关注:HC Wainwright & Co.:维持Oncolytics Biotech"买入"评级,目标价从5美元升至10美元;HC Wainwright & Co.:维持Barinthus Biotherapeutics"买入"评级,目标价从3美元升至4美元
2025-11-18 15:28
花旗上调Bilibili目标价升至27美元; 摩根士丹利上调英伟达目标价升至220美元;Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Stifel analyst Jonathan Siegmann maintains TAT Technologies (NASDAQ:TATT) with a Buy and raises the price target from $44 to $47.
2025-11-15 01:16
TAT Techs (NASDAQ:TATT) is gearing up to announce its quarterly earnings on Wed...
2025-11-11 23:05
Tat Techno ( ($TATT) ) has provided an announcement. Tat Technologies Ltd. anno...
2025-10-21 05:55
今日重点评级关注:Roth Capital:维持Cingulate"买入"评级,目标价从10美元升至17美元;JMP证券:维持BioCryst Pharma"跑赢大市"评级,目标价从17美元升至27美元
2025-10-16 10:43